Follow the Sprint Bioscience AB share price and the full directors' dealings record of the company, a publicly traded company based in Finland. Shares are quoted on the FI market, under the oversight of FIN-FSA. Operating in the Health Care sector, Sprint Bioscience AB has recorded 2 public disclosures. Market capitalisation: €395.7m. The latest transaction was filed on 11 December 2025 (Purchase). Among the most active insiders: Björn Sjöstrand. The full history is openly available.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Sprint Bioscience AB es una empresa sueca centrada en el desarrollo de fármacos para el tratamiento del cáncer. Se especializa en el descubrimiento y desarrollo de nuevas terapias dirigidas.